MetaCap

Freenome Inc. (FRNM)

NASDAQ: FRNMHealth CareMedical SpecialitiesUSD

9.36-0.565 (-5.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FRNM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.28
52-week range
9.28 – 17.50
Day range
9.28 – 9.84
Volume / Avg
621.42K / 833.65K
Beta
—

52-week range

$9.28$17.50

FRNM stock today

Shares of Freenome (FRNM) finished lower on Nov 20 at $9.36, a drop of 5.69% or $0.565 per share, versus the S&P 500's 3.70% decline. Shares are 46.5% below their 52-week high of $17.50, set on Sep 21, 2026 and 0.9% above the 52-week low of $9.28, near the bottom of the past year's range. FRNM is down 28.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.9%.

Freenome has posted a net loss over the last twelve months (EPS of -$1.28), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Freenome

Company profile

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers.

Industry
Medical Specialities
CEO
Mr. Aaron Elliott Ph.D.
Headquarters
Brisbane, CA
Employees
363

Financial highlights

Full financials

Net income was $837,468.

Freenome annual revenue, net income and EPS
Fiscal yearFY 2025
Revenue—
Growth—
Net income$837.47K
EPS (diluted)—

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$18.00+92.31%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$0.01 vs —

FRNM news

All FRNM news

Freenome peers

Health Care sector
FRNM peer companies
CompanyPrice% ChgMarket capCompare
CSTLCastle Biosciences Inc.32.86-1.63%$1.01Bvs FRNM
ALHCAlignment Healthcare Inc.6.37-2.00%$1.33Bvs FRNM
LMRILumexa Imaging Holdings Inc.14.26+1.42%$1.37Bvs FRNM
FLGTFulgent Genetics Inc.24.12-2.66%$673.89Mvs FRNM
TRUPTrupanion Inc.35.56-0.86%$1.54Bvs FRNM
PSNLPersonalis Inc.14.27-3.06%$1.55Bvs FRNM
YDESYD Bio Limited4.83+5.92%$342.12Mvs FRNM
FTREFortrea Holdings Inc.18.55-7.94%$1.79Bvs FRNM

Indexes, lists and sector

Freenome stock FAQ

What is Freenome's stock price today?

FRNM last traded at $9.36 as of Nov 20, 4:00 PM EST, down 5.69% on the day. Prices are delayed at least 15 minutes.

Who is Freenome's CEO?

Mr. Aaron Elliott Ph.D. is the chief executive officer of Freenome Inc., which has about 363 employees.

What is the FRNM 52-week high?

The 52-week high for FRNM is $17.50 and the 52-week low is $9.28. The stock is currently 46.5% below its high.

Compare FRNM